Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adaptimmune Therapeutics ( (ADAP) ) just unveiled an announcement.
On September 6, 2025, Adaptimmune Limited appointed Christopher Hill as Chief Financial Officer, effective September 10, 2025. Hill, with over a decade of experience in financial roles within life science companies, will manage the company’s accounting and finance functions as an independent contractor through a consulting agreement with CJH Financial Limited. This strategic appointment highlights Adaptimmune’s focus on strengthening its financial leadership as it continues to develop its therapeutic offerings.
The most recent analyst rating on (ADAP) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Spark’s Take on ADAP Stock
According to Spark, TipRanks’ AI Analyst, ADAP is a Neutral.
Adaptimmune Therapeutics’ overall stock score is primarily impacted by its weak financial performance and valuation, reflecting significant financial instability and ongoing losses. Technical analysis also indicates bearish momentum. While the earnings call provided some operational positives, recent corporate events, including executive changes and a delisting notice, further contribute to a cautious outlook.
To see Spark’s full report on ADAP stock, click here.
More about Adaptimmune Therapeutics
Adaptimmune Therapeutics is a company operating in the life sciences industry, focusing on developing therapies for autoimmune and fibrotic diseases. The company engages in drug development, with assets ranging from pre-clinical to phase IIb stages.
Average Trading Volume: 35,692,422
Technical Sentiment Signal: Sell
Current Market Cap: $10.87M
See more insights into ADAP stock on TipRanks’ Stock Analysis page.